Simplify Logo

Full-Time

Head of Medical Affairs

Posted on 7/24/2024

Pliant Therapeutics

Pliant Therapeutics

51-200 employees

Develops treatments for fibrotic diseases

Hardware
Biotechnology

Compensation Overview

$370k - $390kAnnually

+ Equity + Bonus

Expert

San Bruno, CA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • MD, PhD, PharmD, or equivalent degree
  • 15+ years of experience in the pharmaceutical/biotech industry in Medical Affairs
  • 8+ years in leadership roles
  • Experience with pulmonary fibrosis (IPF and/or ILD)
  • Experience with building Medical Affairs function in preparation for launch
  • US launch experience
  • Global launch experience is a plus
  • Ability to manage shifting priorities in a rapidly changing environment
  • Strong presentation skills for complex scientific and medical information
  • Experience in real-world evidence strategy
  • Strong writing and reviewing skills
  • Building effective relationships with key opinion leaders
  • Interpersonal skills and team performance optimization
  • Leadership and people management skills
  • Ability to travel domestically and internationally
Responsibilities
  • Designing Medical Affairs strategy
  • Building Medical Affairs organization
  • Overseeing Medical Affairs sub-functions
  • Providing medical/clinical expertise to internal and external stakeholders
  • Identifying relevant medical meetings and congresses
  • Collaborating with cross-functional teams
  • Supporting clinical studies and development activities
  • Developing and managing clinical advisors and KOL relationships
  • Delivering scientific and medical presentations
  • Collaborating with commercial teams
  • Developing early access strategy and plan
  • Creating evidence generation plan for life-cycle strategy
  • Facilitating submission/review processes for Investigator Initiated Studies

Pliant Therapeutics develops treatments for fibrotic diseases, which cause thickening and scarring of connective tissue, leading to organ dysfunction. Their products work by targeting the biological mechanisms behind fibrosis, particularly through the inhibition of integrins, which are proteins that help cells stick together and communicate. This targeted approach allows Pliant to create effective treatments for various fibrotic conditions. Unlike many competitors, Pliant focuses specifically on the science of fibrosis and integrin biology, aiming to reverse the effects of these diseases rather than just manage symptoms. The company's goal is to halt the progression of fibrotic diseases and restore normal organ function, ultimately improving the quality of life for patients.

Company Stage

IPO

Total Funding

$694.9M

Headquarters

San Francisco, California

Founded

2015

Growth & Insights
Headcount

6 month growth

12%

1 year growth

17%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • Pliant's accelerated development of bexotegrast for IPF and positive Phase 2a trial results indicate strong potential for successful market entry.
  • The company's participation in high-profile investor events and scientific congresses enhances its visibility and credibility in the biotech community.
  • Recent strategic appointments, including a new Chief Development Officer and Chief Regulatory Officer, bolster Pliant's leadership team and operational capabilities.

What critics are saying

  • The high costs and long timelines associated with drug development pose financial risks, especially if clinical trials do not meet endpoints.
  • The competitive landscape in biopharmaceuticals, particularly in fibrosis treatment, requires Pliant to continuously innovate to maintain its edge.

What makes Pliant Therapeutics unique

  • Pliant Therapeutics focuses specifically on fibrotic diseases, leveraging deep expertise in fibrosis and integrin biology, unlike competitors with broader therapeutic areas.
  • Their targeted approach to integrin inhibition offers a unique mechanism of action that sets them apart from other fibrosis treatments.
  • Pliant's commitment to rigorous clinical trials and data-driven development ensures high standards of efficacy and safety, distinguishing them in the biopharmaceutical market.
INACTIVE